# Pivotal bioVenture Partners China

> Pivotal bioVenture Partners China is a VC fund backing Biotechnology. See 6 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 6
- Last investment: Dec 2023
- Lead investor: 33%
- Last updated: Aug 2026

Pivotal bioVenture Partners China is a VC fund in Shanghai focused on Biotechnology and Health Care. An Investment Firm based In China.

## Contacts

5 contacts available for Pivotal bioVenture Partners China. Shizune tracks 1 team members at Pivotal bioVenture Partners China. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/pivotal-bioventure-partners-china?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 67% |
| Health Care | 3 | 50% |
| Life Science | 2 | 33% |
| Pharmaceutical | 2 | 33% |
| Medical | 1 | 17% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 50% |
| Seed | 2 | 33% |
| Series A | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 3 | 50% |
| United States | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Vincent Cheung | Founder & Managing Partner | 1 | https://shizune.co/investors/profile/vincent-cheung-2 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Heranova Lifesciences | Hekaiwei is a provider of innovative solutions for women's health. | $3.5M | Seed | Dec 28, 2023 |  |
| Arctic Vision | Arctic Vision is a China-based clinical-stage specialty ophthalmology company with a leading portfolio of breakthrough technologies. The Company's vision is to address ophthalmology's unmet needs through innovative therapies in China, Asia, and globally. Arctic Vision is established by top-tier life sciences investors and led by an eliteteam of ophthalmic industry veterans with substantial and compelling China and global experiences in R&D and commercialization of eye care products. | $100M | Series B | Mar 09, 2021 |  |
| Visen Pharmaceuticals | Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China. | $150M | Series B | Jan 08, 2021 |  |
| Arctic Vision | Arctic Vision is a China-based clinical-stage specialty ophthalmology company with a leading portfolio of breakthrough technologies. The Company's vision is to address ophthalmology's unmet needs through innovative therapies in China, Asia, and globally. Arctic Vision is established by top-tier life sciences investors and led by an eliteteam of ophthalmic industry veterans with substantial and compelling China and global experiences in R&D and commercialization of eye care products. | $32M | Series A | Jul 13, 2020 |  |
| OncXerna Therapeutics | OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform.OncXerna Therapeutics is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company’s deep understanding of how to prospectively identify patients based on the dominant biology of their tumormicroenvironments. This allows OncXerna to pair those patients with OncXerna’s clinical-stage therapies with known mechanisms of action that directly address these biologies, to dramatically improve patient outcomes.The company was founded in 2018 and was formerly known as Oncologie. | $80M | Series B | Jun 10, 2019 |  |
| OncXerna Therapeutics | OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform.OncXerna Therapeutics is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company’s deep understanding of how to prospectively identify patients based on the dominant biology of their tumormicroenvironments. This allows OncXerna to pair those patients with OncXerna’s clinical-stage therapies with known mechanisms of action that directly address these biologies, to dramatically improve patient outcomes.The company was founded in 2018 and was formerly known as Oncologie. | $16.5M | Seed | Jun 07, 2018 |  |

6 of 6 investments shown.

## Co-investors
- [Nan Fung Life Sciences](https://shizune.co/investors/profile/nan-fung-life-sciences) — VC Fund, 6 deals together
- [Morningside](https://shizune.co/investors/profile/morningside-group) — VC Fund, 4 deals together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 2 deals together
- [Volcanics Venture](https://shizune.co/investors/profile/volcanics-venture) — VC Fund, 2 deals together
- CDG Capital — VC Fund, 1 deal together
- [CMB International Capital Corporation](https://shizune.co/investors/profile/cmbi-international-capital-corporation) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Pivotal bioVenture Partners China invest in?

Pivotal bioVenture Partners China invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series B and Seed stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Pivotal bioVenture Partners China?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Pivotal bioVenture Partners China?

The team at Pivotal bioVenture Partners China includes Vincent Cheung (Founder & Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co